The article analyzes in detail the four Fortune 50 pharmaceutical companies in the world, including Hengrui Pharmaceutical, CSPC Pharmaceutical Group, BeiGene, and China Biopharmaceutical, with the highest total assets of China Biopharmaceutical, the largest number of employees of China Biopharmaceutical, the highest revenue and net profit of CSPC Pharmaceutical Group, the best revenue and net profit growth of BeiGene, the highest net profit margin of Hengrui Pharmaceutical, the highest market value of Hengrui Pharmaceutical, the highest R&D expense of BeiGene, and the highest marketing expense of CSPC Pharmaceutical Group. See the table below for details:
Founded in 1997, the company is headquartered in Lianyungang, Jiangsu, and has set up branches in Beijing, Shanghai, Guangdong, Zhejiang, Anhui, Chongqin, Sichuan, Fujian, Henan and other places. A-share listing. The total assets at the end of 2022 were 423600 million yuan, the number of employees is 20,636.
The chairman of the board of directors of the company is Mr. Sun Piaoyang, who graduated from China Pharmaceutical University and Nanjing University with a doctorate degree and is 65 years old. The general manager of the company is Mr. Dai Hongbin, who graduated from Zhongnan University of Economics and Law and Wuhan University with a master's degree, and is 47 years old.
The company is mainly engaged in the research and development, production and sales of anti-tumor, first-class contrast agents and other drugs. Among them, the revenue of anti-tumor drugs accounted for about 53%, * revenue accounted for about 16%, and contrast media revenue accounted for about 13%. Among them, domestic business accounted for about 96%, and overseas business accounted for about 4%.
The company's innovative drug categories rank among the top three in the country, and it has been selected as one of the top 50 pharmaceutical companies in the world and one of the top 500 in China, ranking 493rd.
The company's revenue in 2022 is 212800 million yuan, net profit of 390.6 billion yuan. In the first three quarters of 2023, the company's revenue was 170100 million yuan, a year-on-year increase of 67%, net profit 347.4 billion yuan, a year-on-year increase of 947%, net profit margin 2028%。The current market value is about 290 billion yuan, and the price-earnings ratio is 62 times.
The company's R&D expenses in the first three quarters were 372.5 billion yuan, accounting for 219%, marketing expenses 540.9 billion yuan, accounting for 318%, salary expense 441.1 billion yuan, accounting for 2593%。
Founded in 2010, the company is headquartered in Beijing, and has set up branches in Beijing, Shanghai, Guangzhou, Suzhou and other places. AH and U.S. stock market listings. Total assets at the end of 2022 were 401900 million yuan, 9,212 employees.
The chairman of the board of directors of the company is Mr. Ou Leiqiang, who graduated from MIT and Stanford University with a master's degree and is 55 years old. The general manager of the company is Mr. Wu Xiaobin, who graduated from the University of Konstanz with a doctorate degree and is 62 years old.
The company is mainly engaged in the research, development and sales of innovative drugs, and its main products are anti-tumor drugs such as BRUKINSA and tislelizumab. Among them, the revenue of the two products of BRUKINSA and Baizean accounted for 75%, and the revenue of other cooperation and drugs accounted for 25%. Among them, domestic business accounted for about 52%, and overseas business accounted for about 48%.
The company's R&D investment in innovative drugs ranks first in the country, and the overseas revenue of drugs is among the top three in the industry.
The company's revenue in 2022 is 956.6 billion yuan, with a net profit loss of 136400 million yuan. In the first three quarters of 2023, the company's revenue was 128800 million yuan, a year-on-year increase of 8745%, net profit loss 387.8 billion yuan, a year-on-year increase of 6283%。The current market value is about 200 billion yuan.
The company's R&D expenses in the first three quarters were 917.7 billion yuan, accounting for 7125%, marketing expenses 516.6 billion yuan, accounting for 4011%, salary expense 639.3 billion yuan, accounting for 4965%。
The actual controller of the company is Cai Dongchen. The chairman of the board of directors of the company is Mr. Cai Dongchen, graduated from Nankai University with a master's degree, and is 68 years old. The general manager of the company is Mr. Zhang Cuilong, who graduated from Hebei Medical University with a bachelor's degree and is 55 years old.
The company is mainly engaged in the research and development, production and sales of antibiotics, cardiovascular and cerebrovascular, psychiatric and neurological, and anti-tumor drugs. The company also lays out the processing of drug by-products and the sales of functional foods. Among them, domestic business revenue accounted for about 86%, and overseas business revenue accounted for about 24%.
The company ranks among the top 10 pharmaceutical industry enterprises, the top 50 pharmaceutical companies in the world, and ranks 416th among the top 500 companies in China.
The company's revenue in 2022 is 309400 million yuan, net profit 609.1 billion yuan. In the first three quarters of 2023, the company's revenue was 2386.5 billion yuan, a year-on-year increase of 157%, net profit 449.5 billion yuan, a year-on-year increase of 06%, net profit margin 1946%。The current market value is about 90 billion yuan, and the price-earnings ratio is 13 times.
The company's R&D expenses in the first three quarters were 367.8 billion yuan, accounting for 1541%, marketing expenses 703.2 billion yuan, accounting for 2946%。
Founded in 2000, the company is headquartered in Beijing and Hong Kong, and has set up branches in Beijing, Shanghai, Nanjing, Lianyungang, Qingdao and other places, and is listed on the Hong Kong stock market. The total assets at the end of 2022 were 6406.4 billion yuan, with 26,079 employees.
The actual controller of the company is the Xie Chengrun family. The chairman of the board of directors of the company is Ms. Xie Qirun, who graduated from the University of Pennsylvania with a bachelor's degree and is now 31 years old. The CEO of the company is Mr. Xie Chengrun, who graduated from the University of Pennsylvania with a master's degree and is 27 years old.
The company mainly produces and sells modern preparations of traditional Chinese medicine and western medicine products, involving tumors, analgesia, liver diseases, respiratory and other fields. Among them, the pharmaceutical business accounted for about 98% of the revenue. The company has no overseas business for the time being.
The company was selected as one of the top 50 pharmaceutical companies in the world and one of the top 500 in China, ranking 438th.
The company's revenue in 2022 is 287800 million yuan, net profit of 254.4 billion yuan. Revenue in the first half of 2023 is 152800 million yuan, a year-on-year increase of 055%, net profit 125.9 billion yuan, down 34 percent year-on-year47% and net profit margin of 1767%。The current market value is about 70 billion yuan, and the price-earnings ratio is 34 times.
The company's R&D expenses in the first half of the year were 260.5 billion yuan, accounting for 1705%, marketing expenses 538.2 billion yuan, accounting for 3522%。